668 results on '"O'Donnell, James S."'
Search Results
2. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
3. O-glycan determinants regulate VWF trafficking to Weibel-Palade bodies
4. Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies
5. Glycolytic reprogramming fuels myeloid cell-driven hypercoagulability
6. Novel functions for von Willebrand factor
7. The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1
8. Examining variability in the diagnosis and management of people with bleeding disorders of unknown cause: communication from the ISTH SSC Subcommittee on von Willebrand Factor
9. Unraveling coagulation factor–mediated cellular signaling
10. VWF–ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion
11. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor
12. Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance
13. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A
14. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction
15. Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score
16. Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration
17. Macrophage Galactose Lectin Contributes to the Regulation of FVIII (Factor VIII) Clearance in Mice
18. Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis
19. von Willebrand factor links primary hemostasis to innate immunity
20. Practical treatment guidance for cancer-associated thrombosis – Managing the challenging patient: A consensus statement
21. Therapeutic implications of ongoing alveolar viral replication in COVID-19
22. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis
23. Examining international practices in the management of pregnant women with von Willebrand disease
24. Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy
25. Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
26. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis
27. Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting
28. Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress
29. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis
30. Management of elective procedures in low von Willebrand factor patients in the LoVIC study
31. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease
32. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis
33. Low VWF: insights into pathogenesis, diagnosis, and clinical management
34. Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria
35. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
36. Investigating the clearance of VWF A‐domains using site‐directed PEGylation and novel N‐linked glycosylation
37. Type 1 VWD classification revisited - novel insights from combined analysis of the LoVIC and WiN studies
38. Illustrated State‐of‐the‐Art Capsules of the ISTH 2019 Congress in Melbourne, Australia
39. von Willebrand factor sialylation—A critical regulator of biological function
40. Novel therapies for hemophilia A – the role of the von Willebrand factor chaperone
41. How I treat low von Willebrand factor levels
42. Enhanced thrombin generation potential and endothelial dysfunction in chronic spontaneous urticaria
43. Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor
44. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels
45. R1205H (Vicenza) causes conformational changes in the von Willebrand factor D′D3 domains and enhances von Willebrand factor binding to clearance receptors LRP1 and SR-AI
46. 159 - Von Willebrand Disease and Hemorrhagic Abnormalities of Platelet and Vascular Function
47. GLYCOLYTIC REPROGRAMMING FUELS MYELOID CELL-DRIVEN HYPERCOAGULABILITY
48. Elevated von Willebrand factor levels in multiple myeloma: Dysregulated mechanisms of both secretion and clearance
49. N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance
50. Von Willebrand factor-inflammation crosstalk in deep vein thrombosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.